Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

novocure ltd - NVCR

NVCR

Close Chg Chg %
10.84 -0.29 -2.68%

Closed Market

10.55

-0.29 (2.68%)

Volume: 1.15M

Last Updated:

Apr 2, 2026, 4:00 PM EDT

Trade Now

Company Overview: novocure ltd - NVCR

NVCR Key Data

Open

$10.52

 Day Range

10.30 - 10.87

52 Week Range

9.82 - 20.06

 Market Cap

$1.20B

Shares Outstanding

113.79M

 Public Float

102.40M

Beta

0.82

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.22

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.30M

  

NVCR Performance

1 Week
 
 -3.83%
 
1 Month
 
 -19.10%
 
3 Months
 
 -19.59%
 
1 Year
 
 -36.02%
 
5 Years
 
 -92.09%
 

NVCR Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About novocure ltd - NVCR

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

NVCR At a Glance

NovoCure Ltd.
No. 4 The Forum
St. Helier, Jersey JE2 4UF
Phone 44-15-3475-6700 Revenue 655.35M
Industry Medical Specialties Net Income -136,227,000.00
Sector Health Technology 2025 Sales Growth 8.283%
Fiscal Year-end 12 / 2026 Employees 1,605
View SEC Filings

NVCR Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.199
Price to Book Ratio 4.272
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -8.965
Enterprise Value to Sales 1.88
Total Debt to Enterprise Value 0.202

NVCR Efficiency

Revenue/Employee 408,319.626
Income Per Employee -84,876.636
Receivables Turnover 5.682
Total Asset Turnover 0.641

NVCR Liquidity

Current Ratio 2.897
Quick Ratio 2.713
Cash Ratio 2.05

NVCR Profitability

Gross Margin 74.797
Operating Margin -23.207
Pretax Margin -20.79
Net Margin -20.787
Return on Assets -13.322
Return on Equity -38.886
Return on Total Capital -23.136
Return on Invested Capital -25.835

NVCR Capital Structure

Total Debt to Total Equity 72.945
Total Debt to Total Capital 42.178
Total Debt to Total Assets 30.877
Long-Term Debt to Equity 69.521
Long-Term Debt to Total Capital 40.198
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Novocure Ltd - NVCR

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
537.84M 509.34M 605.22M 655.35M
Sales Growth
+0.53% -5.30% +18.82% +8.28%
Cost of Goods Sold (COGS) incl D&A
114.26M 127.53M 136.18M 165.17M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
10.62M 10.97M 11.23M 14.65M
Depreciation
10.62M 10.97M 11.23M 14.65M
Amortization of Intangibles
- - - -
-
COGS Growth
+0.02% +11.62% +6.77% +21.29%
Gross Income
423.58M 381.80M 469.05M 490.18M
Gross Income Growth
+0.66% -9.86% +22.85% +4.51%
Gross Profit Margin
+78.76% +74.96% +77.50% +74.80%
2022 2023 2024 2025 5-year trend
SG&A Expense
512.50M 607.96M 636.58M 642.27M
Research & Development
206.09M 220.99M 209.37M 224.54M
Other SG&A
306.41M 386.97M 427.21M 417.73M
SGA Growth
+10.34% +18.63% +4.71% +0.89%
Other Operating Expense
- - - -
-
Unusual Expense
611.00K 6.71M 2.96M 1.71M
EBIT after Unusual Expense
(89.52M) (232.87M) (170.50M) (153.80M)
Non Operating Income/Expense
15.79M 46.04M 51.00M 39.77M
Non-Operating Interest Income
15.79M 46.04M 51.00M 39.77M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
8.11M 4.91M 11.66M 22.22M
Interest Expense Growth
-8.21% -39.53% +137.73% +90.49%
Gross Interest Expense
8.11M 4.91M 11.66M 22.22M
Interest Capitalized
- - - -
-
Pretax Income
(81.85M) (191.74M) (131.16M) (136.25M)
Pretax Income Growth
-57.17% -134.27% +31.59% -3.88%
Pretax Margin
-15.22% -37.64% -21.67% -20.79%
Income Tax
10.69M 15.30M 37.47M (23.00K)
Income Tax - Current - Domestic
469.00K 2.16M 3.86M (2.56M)
Income Tax - Current - Foreign
10.22M 13.14M 33.60M 2.53M
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(92.53M) (207.04M) (168.63M) (136.23M)
Minority Interest Expense
- - - -
-
Net Income
(92.53M) (207.04M) (168.63M) (136.23M)
Net Income Growth
-58.58% -123.75% +18.55% +19.21%
Net Margin Growth
-17.20% -40.65% -27.86% -20.79%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(92.53M) (207.04M) (168.63M) (136.23M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(92.53M) (207.04M) (168.63M) (136.23M)
EPS (Basic)
-0.8841 -1.946 -1.5638 -1.2221
EPS (Basic) Growth
-56.73% -120.11% +19.64% +21.85%
Basic Shares Outstanding
104.66M 106.39M 107.83M 111.47M
EPS (Diluted)
-0.8841 -1.946 -1.5638 -1.2221
EPS (Diluted) Growth
-56.73% -120.11% +19.64% +21.85%
Diluted Shares Outstanding
104.66M 106.39M 107.83M 111.47M
EBITDA
(78.29M) (215.19M) (156.30M) (137.44M)
EBITDA Growth
-134.09% -174.87% +27.36% +12.07%
EBITDA Margin
-14.56% -42.25% -25.83% -20.97%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 25.929
Number of Ratings 8 Current Quarters Estimate -0.368
FY Report Date 06 / 2026 Current Year's Estimate -1.535
Last Quarter’s Earnings -0.41 Median PE on CY Estimate N/A
Year Ago Earnings -1.22 Next Fiscal Year Estimate -1.165
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 7 7 7
Mean Estimate -0.37 -0.34 -1.54 -1.17
High Estimates -0.28 -0.26 -1.15 -0.62
Low Estimate -0.47 -0.41 -1.88 -1.42
Coefficient of Variance -15.76 -13.58 -18.77 -23.05

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 6 5
OVERWEIGHT 0 0 0
HOLD 2 2 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Novocure Ltd - NVCR

Date Name Shares Transaction Value
Mar 6, 2026 Uri Weinberg Chf Medical and Innovation Ofr 73,340 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2026 Mukund Paravasthu Chief Operating Officer 66,006 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2026 Mukund Paravasthu Chief Operating Officer 7,518 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2026 Mukund Paravasthu Chief Operating Officer 72,832 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $13.77 per share 1,002,896.64
Mar 6, 2026 Mukund Paravasthu Chief Operating Officer 116,078 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $13.31 per share 1,544,998.18
Mar 6, 2026 Mukund Paravasthu Chief Operating Officer 121,455 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2026 Michal Nath Puri Chief Human Resources Officer 58,672 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2026 Michal Nath Puri Chief Human Resources Officer 201,322 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $13.31 per share 2,679,595.82
Mar 6, 2026 Michal Nath Puri Chief Human Resources Officer 202,422 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2026 Barak Ben Arye General Counsel 73,340 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2026 Barak Ben Arye General Counsel 242,453 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2026 Frank Leonard Chief Executive Officer 499,400 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2026 Uri Weinberg Chf Medical and Innovation Ofr 267,190 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $13.31 per share 3,556,298.90
Mar 6, 2026 Uri Weinberg Chf Medical and Innovation Ofr 273,602 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2026 Christoph Brackmann Chief Financial Officer 80,674 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2026 Christoph Brackmann Chief Financial Officer 182,842 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $13.31 per share 2,433,627.02
Mar 6, 2026 Christoph Brackmann Chief Financial Officer 189,254 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2026 Nicolas Leupin Former Chief Medical Officer 102,979 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $13.31 per share 1,370,650.49
Mar 6, 2026 Ashley Cordova Former Chief Executive Officer 422,570 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $13.3 per share 5,620,181.00
Mar 6, 2026 Frank Leonard Chief Executive Officer 216,388 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Novocure Ltd in the News